Recursion Pharmaceuticals (NASDAQ: RXRX), and CRISPR Therapeutics (NASDAQ: CRSP), plunged in March, with the stocks down 35.3 ...

Chinese drug makers landed 33 licensing deals with overseas pharmaceutical firms, with transactions totalling US$36.2 billion ...

KLP Kapitalforvaltning AS acquired a new stake in Biohaven Ltd. (NYSE:BHVN – Free Report) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 16,100 shares of the ...

American Century Companies Inc. increased its position in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) by 9.5% during ...

American Century Companies has boosted its stake in Biohaven (BHVN) by 9.5% during Q4, ETF Daily News reports, citing a recent SEC filing. The firm owned 558,761 shares of Biohaven after purchasing an ...

More than three-quarters of private biotech investment tracked by BioPharma Dive between January and March was distributed ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Using the 2 Stage Free Cash Flow to Equity, Biohaven fair value estimate is US$28.35 With US$31.37 share price, Biohaven appears to be trading close to its estimated fair value The US$64.20 ...

Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd ("Biohaven" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

Deutsche Bank says Biohaven’s (BHVN) competitor Immunovant (IMVT) reported topline data for FcRn antibody batoclimab in myasthenia gravis and ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Thursday, shares of Biohaven Ltd (Symbol: BHVN) entered into oversold territory, hitting an RSI reading of 29. ...